Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05405556
Other study ID # 2022P000454
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 17, 2022
Est. completion date November 2023

Study information

Verified date January 2023
Source Brigham and Women's Hospital
Contact Martina M McGrath, MBBCh
Phone 6177325500
Email mmcgrath8@bwh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigator-initiated, randomized controlled trial in adult KTRs (N=50) with stable allograft function to assess: 1) the reversibility of the expected acute changes in eGFR with sotagliflozin (donated by Lexicon); 2) proportion of patients completing the protocol according to different eGFR reporting strategies (using a predefined algorithm to manage the expected pharmacological effect of sotagliflozin on eGFR); 3) safety and tolerability of sotagliflozin.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date November 2023
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults =18 years - Recipients of kidney transplant with stable eGFR* - eGFR-creatinine (CKD-EPI 2021) =25 mL/min/1.73 m2 - Informed consent - Stable eGFR will be ascertained by careful chart review establishing that the patient's current graft has been functioning for at least 12 months post-transplantation, patients have not been treated for acute rejection within the prior 3 months, and a creatinine-based eGFR is stable (two consecutive measurements separated by at least 28 days within 5 mL/min/1.73 m2) and =25 mL/min/1.73 m2. Exclusion Criteria: - Recurrent urinary tract infections (>2 episodes/year or antibiotic prophylaxis) - Biopsy-proven acute rejection within 12 weeks - Screening serum potassium >5.5 mmol/L - Uncontrolled hypertension (systolic blood pressure >180/100 mmHg) - New York Heart Association (NYHA) Class IV HF - Myocardial infarction, unstable angina, revascularization procedure (e.g., stent or bypass graft surgery), or cerebrovascular accident within 12 weeks - History of diabetic ketoacidosis - Type 1 Diabetes Mellitus - Hereditary glucose-galactose malabsorption or primary renal glucosuria - Liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis); Alanine aminotransferase (ALT) levels >2.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN, unless consistent with Gilbert's disease - Malignancy within 5 years (exceptions: squamous and basal cell carcinomas of the skin and carcinoma of the cervix in situ, or a malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence) - Human immunodeficiency virus antibody positive - Major surgery within 12 weeks - Atraumatic amputation within past 12 months of screening, or an active skin ulcer, osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening - Combination use of ACEi and ARB - Current use of an SGLT2 inhibitor (within 12 weeks prior to randomization) - Known allergies, hypersensitivity, or intolerance to SGLT2i or its excipients - Digoxin plasma level >1.2 ng/mL - Clofibrate, fenofibrate, dronedarone, or ranolazine treatment that has not been at a stable dose in the 30 days prior to screening or randomization, or a dose adjustment is expected - Received an active investigational drug (including vaccines) other than a placebo agent, or used an investigational medical device within 12 weeks before Day 1/baseline - Pregnant or breast-feeding or planning to become pregnant or breast-feed during the study - Women of childbearing potential not willing to use a highly-effective method(s) of birth control, or who are unwilling or unable to be tested for pregnancy - Any condition that in the opinion of the investigator would make participation not in the best interest of the subject

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
eGFR reporting
To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows: only study-related eGFR values >25% below baseline will be reported to patients and providers all study-related eGFR will be provided to patients and providers

Locations

Country Name City State
United States Brigham and Women's Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Martina McGrath, MD

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Diaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Safety Assessments - Acute changes in eGFR (baseline to 4 weeks) 4 weeks
Other Safety Assessments - Longer-term changes in eGFR (baseline to 12 weeks and 4 weeks to 12 weeks) 12 weeks
Other Safety Assessments - Reversibility of changes in eGFR (12 to 16 weeks - after drug discontinuation) Weeks 12-16 (off-drug)
Other Safety Assessments - Acute Kidney Injury (>50% increase in serum creatinine/40% decline in eGFR within one week), which will be assessed throughout the on-drug period of 12 weeks 12 weeks
Other Safety Assessments - All adverse events (AEs) 12 weeks
Other Safety Assessments - All serious adverse events (SAEs) 12 weeks
Other Safety Assessments - Diarrhea 12 weeks
Other Safety Assessments - Infection requiring treatment with anti-microbials (including urogenital infection and urinary tract infections) 12 weeks
Other Safety Assessments - Severe hypoglycemia (event that requires assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions) 12 weeks
Other Safety Assessments - Diabetic ketoacidosis 12 weeks
Other Safety Assessments - Hyperkalemia (>5.5 mmol/L) 12 weeks
Other Safety Assessments - Hypotension (symptomatic SBP <90 mmHg or hypotension requiring adjustment in blood pressure medications or treatment in an emergency or hospitalized setting) 12 weeks
Other Tolerability Assessments - Proportion of participants able to complete the full 12 weeks of treatment, according to randomized arm 12 weeks
Other Tolerability Assessments - Study medication discontinuation rates 12 weeks
Other Tolerability Assessments - KDQOL-36 questionnaire 12 weeks
Primary Reversibility of eGFR changes Following 12 weeks of open-label drug treatment, participants will stop drug and be followed for a further four weeks (16 weeks total). Reversibility will be assessed as the proportion of patients who return to baseline eGFR (+/- 10%) by the end of the 4-week off-treatment period. 16 weeks total
Secondary Proportion of patients successfully completing the full treatment protocol, according to randomized groups Following 12 weeks of open-label drug treatment, participants will stop drug and be followed for a further four weeks. The proportion of patients completing the full 16 weeks will be compared according to randomized groups. 16 weeks total
See also
  Status Clinical Trial Phase
Completed NCT04087720 - Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant Phase 4
Completed NCT03749356 - Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients Phase 4
Withdrawn NCT05811468 - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT00498576 - Melatonin and Adiponectin in Hypertensive Kidney Transplant N/A
Completed NCT00642655 - Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation Phase 1/Phase 2
Completed NCT00374400 - The Paired Donation Consortium Paired Donation Program N/A
Completed NCT01710033 - A Study Of CP-690,550 In Stable Kidney Transplant Patients Phase 1
Completed NCT00205257 - Prediction of Acute Rejection in Renal Transplant Phase 1
Completed NCT02711826 - Treg Therapy in Subclinical Inflammation in Kidney Transplantation Phase 1/Phase 2
Withdrawn NCT03978494 - Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients. Phase 1
Completed NCT03837522 - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies N/A
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT05029310 - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients Phase 4
Completed NCT03644485 - Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients Phase 4
Active, not recruiting NCT02409901 - Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients N/A
Completed NCT01047410 - ACtive Care After Transplantation, the ACT Study N/A
Completed NCT00940940 - Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Phase 4
Completed NCT00217126 - The Study of Long-term Deterioration of Kidney Transplants. Phase 4
Completed NCT00270712 - A Study of Factors That Affect Long-Term Kidney Transplant Function